Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-2542
Dr. Courtney is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kevin Courtney is an oncology specialist based in Dallas, TX. He specializes in the treatment of genitourinary malignancies. Dr. Courtney completed his Ph.D. in Molecular Cancer Biology at Duke University School of Medicine in 2001, and he received his M.D. from Duke University School of Medicine in 2002. He completed his medical residency in internal medicine at the University of California, San Francisco, followed by a fellowship in medical oncology at Dana-Farber / Harvard Cancer Center. His expertise centers on genitourinary medical oncology, with a focus on clinical and translational research in prostate and kidney cancer. He is a physician scientist who has authored multiple peer-reviewed publications. He holds certifications from Epic Systems Corporation related to meaningful use of electronic health records.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
University of California (San Francisco)Residency, Internal Medicine, 2002 - 2005
Duke University School of MedicineClass of 2002
Certifications & Licensure
TX State Medical License 2012 - 2027
MA State Medical License 2005 - 2012
CA State Medical License 2004 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013, 2015-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Publications & Presentations
PubMed
- Differential Tumor Response Patterns and Extent of Necrosis After Immunotherapy Combinations Predict Clinical Responses for Renal Cell Carcinoma.Wadih Issa, Nicolas Sayegh, Damla Gunenc, Navneet Kaur, Andrew DeVilbiss
Clinical Genitourinary Cancer. 2026-06-01 - Real-World Treatment Outcomes in Patients With Ga68-PSMA-PET Positive Metastatic Hormone-Sensitive Prostate Cancer With or Without Conventional Imaging Correlates.Wadih Issa, Maureen Aliru, Song Zhang, Damla Gunenc, Changchuan Jiang
Clinical Genitourinary Cancer. 2026-02-01 - Stereotactic Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer: Final Results of a Phase 2b Trial.Raquibul Hannan, Ryan Assadi, Alana Christie, Varsha Puliyadi, Aurelie Garant
European Urology Oncology. 2026-01-03
Journal Articles
- Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the in Vitro Integrity of T-cells from Cancer PatientsKevin Courtney, Yull Arriaga, Barbara Haley, John C Mansour, Ponciano D Cruz, David Harker, Farshid Araghizadeh, Clinical Cancer Research
Press Mentions
UTSW’s Simmons Cancer Center Awarded More Than $11.5 Million in CPRIT FundingSeptember 6th, 2024- Children’s Research Institute at UT Southwestern Scientists Discover Kidney Cancers Rely on Mitochondrial Metabolism to MetastasizeAugust 14th, 2024
Findings Establish PT2385 as a Highly Specific HIF-2 Inhibitor for Patients with Clear Cell RCCFebruary 27th, 2020
Grant Support
- North American Star ConsortiumUNIVERSITY HEALTH NETWORK2026–2027
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
